ALMS NASDAQ
Alumis Inc. Common Stock
1W: -10.0%
1M: -14.4%
3M: -20.7%
YTD: +147.4%
1Y: +354.3%
$22.02
-0.15 (-0.68%)
Weekly Expected Move ±8.5%
$19
$21
$23
$25
$27
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (37)
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Why Is Alumis Stock Falling Monday?
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B
Top performing mid-cap stocks YTD as volatility hits markets
Alumis reports FY results
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Alumis to Present at the Leerink Partners Global Healthcare Conference
Alumis to Present at the Leerink Partners Global Healthcare Conference
AXQ Capital LP Invests $78,000 in Alumis Inc. $ALMS
Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS
Alumis to Participate in Upcoming February Investor Conferences
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
Alumis Inc. (NASDAQ:ALMS) Short Interest Up 93.1% in January
An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million
Alumis (NASDAQ:ALMS) Trading 6.6% Higher Following Insider Buying Activity
Alumis (NASDAQ:ALMS) Major Shareholder Foresite Labs, Llc Purchases 411,764 Shares
Alumis (NASDAQ:ALMS) Director Srinivas Akkaraju Acquires 588,235 Shares of Stock
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Alumis Announces Pricing of Upsized Public Offering of Common Stock
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise
Alumis Shares Jump as Envudeucitinib Hits Phase III Endpoints in Psoriasis, NDA Planned for 2026
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib
Alumis Announces Proposed Public Offering of Common Stock
Alumis Stock Hits Record High on Psoriasis Drug Trial Results
Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars
Alumis skin disease drug meets main goal of two late-stage trials
Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis